The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy
Open accessAbstract
IMPORTANCE: Overdiagnosis and overtreatment of indolent prostate cancer (PCA) is a serious health issue in most developed countries. There is an unmet clinical need for noninvasive, easy to administer, diagnostic assays to help assess whether a prostate biopsy is warranted. OBJECTIVE: To determine the performance of a novel urine exosome gene expression assay (the ExoDx Prostate IntelliScore urine exosome assay) plus standard of care (SOC) (ie, prostate-specific antigen [PSA] level, age, race, and family history) vs SOC alone for discriminating between Gleason score (GS)7 and GS6 and benign disease on initial biopsy. DESIGN, SETTING, AND PARTICIPANTS: In training, using reverse-transcriptase polymerase chain reaction (PCR), we compared the urine exosome gene expression assay with biopsy outcomes in 499 patients with prostate-specific antigen (PSA) levels of 2 to 20 ng/mL. The derived prognostic score was then validated in 1064 patients from 22 community practice and academic urology clinic sites in the United States. Eligible participants included PCA-free men, 50 years or older, scheduled for an initial or repeated prostate needle biopsy due to suspicious digital rectal examination (DRE) findings and/or PSA levels (limit range, 2.0-20.0 ng/mL). MAIN OUTCOMES AND MEASURES: Evaluate the assay using the area under receiver operating characteristic curve (AUC) in discrimination of GS7 or greater from GS6 and benign disease on initial biopsy. RESULTS: In 255 men in the training target population (median age 62 years and median PSA level 5.0 ng/mL, and initial biopsy), the urine exosome gene expression assay plus SOC was associated with improved discrimination between GS7 or greater and GS6 and benign disease: AUC 0.77 (95% CI, 0.71-0.83) vs SOC AUC 0.66 (95% CI, 0.58-0.72) (P < .001). Independent validation in 519 patients' urine exosome gene expression assay plus SOC AUC 0.73 (95% CI, 0.68-0.77) was superior to SOC AUC 0.63 (95% CI, 0.58-0.68) (P < .001). Using a predefined cut point, 138 of 519 (27%) biopsies would have been avoided, missing only 5% of patients with dominant pattern 4 high-risk GS7 disease. CONCLUSIONS AND RELEVANCE: This urine exosome gene expression assay is a noninvasive, urinary 3-gene expression assay that discriminates high-grade (≥GS7) from low-grade (GS6) cancer and benign disease. In this study, the urine exosome gene expression assay was associated with improved identification of patients with higher-grade prostate cancer among men with elevated PSA levels and could reduce the total number of unnecessary biopsies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DeLong, E. R., DeLong, D. M., & Clarke-Pearson, D. L. (1988) · Biometrics · doi:10.2307/2531595 · Cited by 22,649
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,293
Valadi, H., Ekström, K., Bossios, A., Sjöstrand, M., Lee, J. J., & Lötvall, J. O. (2007) · Nature Cell Biology · doi:10.1038/ncb1596 · Cited by 12,834
Siegel, R., Ma, J., Zou, Z., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21208 · Cited by 11,499
Skog, J., Würdinger, T., van Rijn, S., Meijer, D. H., Gainche, L., Curry, W. T., Carter, B. S., Krichevsky, A. M., & Breakefield, X. O. (2008) · Nature Cell Biology · doi:10.1038/ncb1800 · Cited by 5,001
Self-citationScreening and Prostate-Cancer Mortality in a Randomized European Study
Schröder, F. H., Hugosson, J., Roobol, M. J., Tammela, T. L. J., Ciatto, S., Nelen, V., Kwiatkowski, M., Lujan, M., Lilja, H., Zappa, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810084 · Cited by 4,014
Mortality Results from a Randomized Prostate-Cancer Screening Trial
Andriole, G. L., Crawford, E. D., Grubb, R. L., Buys, S. S., Chia, D., Church, T. R., Fouad, M. N., Gelmann, E. P., Kvale, P. A., Reding, D. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810696 · Cited by 2,906
Self-citationScreening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement
Moyer, V. A., & on behalf of the U.S. Preventive Services Task Force* (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-2-201207170-00459 · Cited by 2,522
Thompson, I. M., Pauler, D. K., Goodman, P. J., Tangen, C. M., Lucia, M. S., Parnes, H. L., Minasian, L. M., Ford, L. G., Lippman, S. M., Crawford, E. D., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031918 · Cited by 2,446
Self-citationRadical Prostatectomy versus Observation for Localized Prostate Cancer
Wilt, T. J., Brawer, M. K., Jones, K. M., Barry, M. J., Aronson, W. J., Fox, S., Gingrich, J. R., Wei, J. T., Gilhooly, P., Grob, B. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113162 · Cited by 1,770
Self-citationSchröder, F. H., Hugosson, J., Roobol, M. J., Tammela, T. L. J., Zappa, M., Nelen, V., Kwiatkowski, M., Lujan, M., Määttänen, L., Lilja, H., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60525-0 · Cited by 1,566
Early Detection of Prostate Cancer: AUA Guideline
Carter, H. B., Albertsen, P. C., Barry, M. J., Etzioni, R., Freedland, S. J., Greene, K. L., Holmberg, L., Kantoff, P., Konety, B. R., Murad, M. H., et al. (2013) · Journal of Urology · doi:10.1016/j.juro.2013.04.119 · Cited by 1,242
Systematic Review of Complications of Prostate Biopsy
Loeb, S., Vellekoop, A., Ahmed, H. U., Catto, J., Emberton, M., Nam, R., Rosario, D. J., Scattoni, V., & Lotan, Y. (2013) · European Urology · doi:10.1016/j.eururo.2013.05.049 · Cited by 1,073
Radical Prostatectomy or Watchful Waiting in Early Prostate Cancer
Bill-Axelson, A., Holmberg, L., Garmo, H., Rider, J. R., Taari, K., Busch, C., Nordling, S., Häggman, M., Andersson, S.-O., Spångberg, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1311593 · Cited by 981
Assessing Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial
Thompson, I. M., Ankerst, D. P., Chi, C., Goodman, P. J., Tangen, C. M., Lucia, M. S., Feng, Z., Parnes, H. L., & Coltman, C. A. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj131 · Cited by 938
Self-citationProstate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer
Nilsson, J., Skog, J., Nordstrand, A., Baranov, V, Mincheva-Nilsson, L., Breakefield, X. O., & Widmark, A. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605058 · Cited by 776
Self-citationNam, R. K., Saskin, R., Lee, Y., Liu, Y., Law, C., Klotz, L. H., Loblaw, D. A., Trachtenberg, J., Stanimirovic, A., Simor, A. E., et al. (2013) · Journal of Urology · doi:10.1016/j.juro.2012.11.015 · Cited by 592
Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations
Jemal, A., Fedewa, S. A., Ma, J., Siegel, R., Lin, C. C., Brawley, O., & Ward, E. M. (2015) · JAMA · doi:10.1001/jama.2015.14905 · Cited by 469
Nucleic acids within urinary exosomes/microvesicles are potential biomarkers for renal disease
Miranda, K. C., Bond, D. T., McKee, M., Skog, J., Păunescu, T. G., Da Silva, N., Brown, D., & Russo, L. M. (2010) · Kidney International · doi:10.1038/ki.2010.106 · Cited by 408
Self-citationUrine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment
Tomlins, S. A., Day, J. R., Lonigro, R. J., Hovelson, D. H., Siddiqui, J., Kunju, L. P., Dunn, R. L., Meyer, S., Hodge, P., Groskopf, J., et al. (2016) · European Urology · doi:10.1016/j.eururo.2015.04.039 · Cited by 393
Self-citationLeyten, G. H. J. M., Hessels, D., Jannink, S. A., Smit, F. P., de Jong, H., Cornel, E. B., de Reijke, T. M., Vergunst, H., Kil, P., Knipscheer, B. C., et al. (2014) · European Urology · doi:10.1016/j.eururo.2012.11.014 · Cited by 352
Cullen, J., Rosner, I. L., Brand, T. C., Zhang, N., Tsiatis, A. C., Moncur, J., Ali, A., Chen, Y., Knezevic, D., Maddala, T., et al. (2015) · European Urology · doi:10.1016/j.eururo.2014.11.030 · Cited by 310
The Prostate Health Index Selectively Identifies Clinically Significant Prostate Cancer
Loeb, S., Sanda, M. G., Broyles, D. L., Shin, S. S., Bangma, C. H., Wei, J. T., Partin, A. W., Klee, G. G., Slawin, K. M., Marks, L. S., et al. (2015) · Journal of Urology · doi:10.1016/j.juro.2014.10.121 · Cited by 300
Self-citationOutcomes of Active Surveillance for Men With Intermediate-Risk Prostate Cancer
Cooperberg, M. R., Cowan, J. E., Hilton, J. F., Reese, A. C., Zaid, H. B., Porten, S. P., Shinohara, K., Meng, M. V., Greene, K. L., & Carroll, P. R. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.4252 · Cited by 283
Self-citationCan Urinary PCA3 Supplement PSA in the Early Detection of Prostate Cancer?
Wei, J. T., Feng, Z., Partin, A. W., Brown, E., Thompson, I., Sokoll, L., Chan, D. W., Lotan, Y., Kibel, A. S., Busby, J. E., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.8505 · Cited by 274
Self-citationOettgen, P., Finger, E., Sun, Z., Akbarali, Y., Thamrongsak, U., Boltax, J., Grall, F., Dube, A., Weiss, A., Brown, L., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.2.1216 · Cited by 268
Taneja, S. S. (2015) · Journal of Urology · doi:10.1016/j.juro.2015.02.070 · Cited by 228
Nordström, T., Vickers, A., Assel, M., Lilja, H., Grönberg, H., & Eklund, M. (2015) · European Urology · doi:10.1016/j.eururo.2014.08.010 · Cited by 217
Donovan, M. J., Noerholm, M., Bentink, S., Belzer, S., Skog, J., O'Neill, V, Cochran, J. S., & Brown, G. A. (2015) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2015.40 · Cited by 172
Self-citationGittelman, M., Hertzman, B., Bailen, J. L., Williams, T., Koziol, I., Henderson, R. J., Efros, M. D., Bidair, M., & Ward, J. F. (2013) · The Journal of Urology · doi:10.1016/j.juro.2013.02.018 · Cited by 145
John, J. S., Powell, K., & Conley‐LaComb, M. K. (2012) · Journal of Cancer Science & Therapy · doi:10.4172/1948-5956.1000119 · Cited by 139
Miranda, K. C., Bond, D. T., Levin, J. Z., Adiconis, X., Sivachenko, A., Russ, C., Brown, D., Nusbaum, C., & Russo, L. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096094 · Cited by 139
Screening and Prostate-Cancer Mortality in a Randomized European Study
Lawton, C. A. (2010) · Yearbook of Oncology · doi:10.1016/s1040-1741(09)79428-x · Cited by 138
Barocas, D. A., Mallin, K., Graves, A. J., Penson, D. F., Palis, B. E., Winchester, D. P., & Chang, S. S. (2015) · The Journal of Urology · doi:10.1016/j.juro.2015.06.075 · Cited by 126
Chevli, K., Duff, M., Walter, P., Yu, C., Capuder, B., Elshafei, A., Malczewski, S., Kattan, M. W., & Jones, J. S. (2013) · The Journal of Urology · doi:10.1016/j.juro.2013.12.005 · Cited by 121
Self-citationBrain Tumor Microvesicles: Insights into Intercellular Communication in the Nervous System
van der Vos, K. E., Balaj, L., Skog, J., & Breakefield, X. O. (2011) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-011-9697-y · Cited by 112
Self-citationProstate Cancer Biomarker Profiles in Urinary Sediments and Exosomes
Dijkstra, S., Birker, I. L., Smit, F. P., Leyten, G. H. J. M., de Reijke, T. M., van Oort, I. M., Mulders, P., Jannink, S. A., & Schalken, J. A. (2013) · The Journal of Urology · doi:10.1016/j.juro.2013.11.001 · Cited by 111
Braun, K., Sjoberg, D. D., Vickers, A. J., Lilja, H. G., & Bjartell, A. S. (2015) · European Urology · doi:10.1016/j.eururo.2015.04.028 · Cited by 104
Nationwide Population Based Study of Infections after Transrectal Ultrasound Guided Prostate Biopsy
Lundström, K., Drevin, L., Carlsson, S., Garmo, H., Loeb, S., Stattin, P. E., & Bill‐Axelson, A. (2014) · The Journal of Urology · doi:10.1016/j.juro.2014.04.098 · Cited by 102
Epidemiology, Etiology, and Prevention of Prostate Cancer
Abouassaly, R., Thompson, I. M., Platz, E. A., & Klein, E. A. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4160-6911-9.00095-5 · Cited by 97
Self-citationCheng, X., Black, M., Ustiyan, V., Le, T. T., Fulford, L., Sridharan, A., Medvedovic, M., Kalinichenko, V. V., Whitsett, J. A., & Kalin, T. V. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004656 · Cited by 88
Vickers, A. J., Cronin, A. M., Aus, G., Pihl, C., Becker, C., Pettersson, K. S. I., Scardino, P. T., Hugosson, J., & Lilja, H. G. (2010) · Cancer · doi:10.1002/cncr.25010 · Cited by 78
Active surveillance versus radical treatment for favorable-risk localized prostate cancer
Klotz, L. H. (2006) · Current Treatment Options in Oncology · doi:10.1007/s11864-006-0003-z · Cited by 69
Amin, A., Partin, A. W., & Epstein, J. I. (2011) · The Journal of Urology · doi:10.1016/j.juro.2011.05.075 · Cited by 61
Self-citationEyre, S. J., Ankerst, D. P., Wei, J. T., Nair, P. V., Regan, M. M., Bueti, G., Tang, J. M., Rubin, M. A., Kearney, M., Thompson, I. M., et al. (2009) · The Journal of Urology · doi:10.1016/j.juro.2009.08.056 · Cited by 54
Self-citationHe, J., Schepmoes, A., Shi, T., Wu, C., Fillmore, T., Gao, Y., Smith, R. D., Qian, W., Rodland, K., Liu, T., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0418-z · Cited by 28
High SPDEF may identify patients who will have a prolonged response to androgen deprivation therapy
Haller, A., Tan, W., Ondracek, R. P., Underwood, W., Tian, L., Morrison, C., & Li, F. (2013) · The Prostate · doi:10.1002/pros.22770 · Cited by 14
Cited by
New Technologies for Analysis of Extracellular Vesicles
Shao, H., Im, H., Castro, C. M., Breakefield, X., Weissleder, R., & Lee, H. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00534 · Cited by 1,675
Extracellular vesicles in cancer — implications for future improvements in cancer care
Xu, R., Rai, A., Chen, M., Suwakulsiri, W., Greening, D. W., & Simpson, R. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0036-9 · Cited by 1,445
Exosomes in cancer development, metastasis, and immunity
Zhang, L., & Yu, D. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.04.004 · Cited by 870
Exosome-based liquid biopsies in cancer: opportunities and challenges
Yu, W., Hurley, J., Roberts, D., Chakrabortty, S. K., Enderle, D., Noerholm, M., Breakefield, X. O., & Skog, J. K. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.01.074 · Cited by 870
Self-citationExosomes as a new frontier of cancer liquid biopsy
Yu, D., Li, Y., Wang, M., Gu, J., Xu, W., Cai, H., Fang, X., & Zhang, X. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01509-9 · Cited by 855
Metadata
- Authors
- McKiernan, J., Donovan, M. J., O’Neill, V., Bentink, S., Noerholm, M., Belzer, S., Skog, J., Kattan, M. W., Partin, A., Andriole, G., Brown, G., Wei, J. T., Thompson, I. M., & Carroll, P.
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2016-07-01
- Volume
- 2
- Issue
- 7
- Pages
- 882
- ISSN
- 2374-2437 (ISSN-L)
- OpenAlex
- W2316242722
- Cited by
- 674
- References
- 48
- FWCI
- 42.90
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.